158 related articles for article (PubMed ID: 36373415)
1. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
2. AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Moosavi Baigi F
Toxicol Appl Pharmacol; 2023 May; 466():116470. PubMed ID: 36933622
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
[TBL] [Abstract][Full Text] [Related]
4. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
[TBL] [Abstract][Full Text] [Related]
5. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
6. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
Amiri Darban S; Nikoofal-Sahlabadi S; Amiri N; Kiamanesh N; Mehrabian A; Zendehbad B; Gholizadeh Z; Jaafari MR
Colloids Surf B Biointerfaces; 2018 Apr; 164():107-115. PubMed ID: 29413587
[TBL] [Abstract][Full Text] [Related]
7. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
8. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
9. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
10. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
12. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
13. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
16. Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells.
Amin M; Bagheri M; Mansourian M; Jaafari MR; Ten Hagen TL
Int J Nanomedicine; 2018; 13():7441-7455. PubMed ID: 30532532
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
18. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
20. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
